research Determination of vinflunine in Beagle dog′s plasma by LC-MS and study of its pharmacokinetics
The method accurately measures vinflunine in dog plasma.
Search
for
Sort by
Research
270-300 / 1000+ resultsresearch Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient
Leflunomide successfully treated a rare skin condition in a liver transplant patient.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Alopecia associated with ritonavir-boosted atazanavir therapy
A man's hair loss was linked to his HIV medication, which improved after changing drugs.
research Anticancer activity of cepharanthine on non-small cell lung cancer cells
Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.
research Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Referee report. For: Drug utilization pattern and adverse drug reactions of chemotherapy in pediatric patients at Muhimbili National Hospital, Tanzania [version 1; peer review: 1 approved, 1 approved with reservations]
Most pediatric cancer patients at Muhimbili National Hospital experienced adverse drug reactions during chemotherapy, highlighting the need for careful monitoring.
research Hair Re-Pigmentation After Nilotinib
Nilotinib may cause gray hair to return to its original color.
research A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4
The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.
research Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine
Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
research Primary cutaneous diffuse large B‑cell lymphoma of the scalp: A case report and brief review of the literature
Lymphoma should be considered in unusual scalp hair loss cases, as treatment can work but may lead to severe complications.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research Topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a phase I safety study.
Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
research Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA® analysis system
Topical ruxolitinib quickly improves non-segmental vitiligo.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research Use of the drug Wolvit® (biotin 5 mg) in treatment of defuse telogenous alopecia
Wolvit® (biotin 5 mg) is effective and safe for treating hair loss and scalp conditions in women.
research Abstract P1-09-32: A novel candidate for chemotherapy induced alopecia (CIA) through local modulation of apoptosis and inflammation
A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.
research Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.
research Alternative Therapies for Vitiligo
Some alternative therapies for vitiligo show promise but need more research.
research The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial
DHL-HisZnNa may help reduce hair loss from chemotherapy, but more research is needed.
research Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Abstracts
Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
research Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib
Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
research 471 Senolytic Potential of Fisetin and ABT Compounds in Dermal Fibroblasts
research Serum and liver tissue biotinidase enzyme activity in rats which were administrated to valproic acid
Valproic acid may cause hair loss by reducing biotinidase enzyme activity in rats.
research Severe Pustular Drug Eruptions From Amivantamab: A Case Series
Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.